GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to ...
The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...
The first time Dr. Fajgenbaum repurposed a drug, it was in an attempt to save his own life. At 25, while in medical school, ...
In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.
Recent breakthroughs by The Institute of Cancer Research in London and the University of Virginia in the U.S. could cut drug ...
In this week’s edition of the biotech bi-weekly, learn more about Thermo Fisher’s new system for automating complex sample ...
Based on Intelligencia AI’s comprehensive, proprietary database of over 20,000 industry-sponsored, interventional oncology clinical programs (around 12,400 clinical trials), recent insights highlight ...
The return on investment in pharma research and development (R&D) has increased from the previous year, with GLP-1 drugs ...
Joseph Coates, left, owes his life to an A.I. model developed by ... said Christine Colvis, who heads drug development partnership programs at NCATS. That’s what makes drug repurposing such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback